Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Reinisch

Showing results (221-230 of 352) with videos related to

Pageof 36
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 30, 2019
Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug DevelopmentWalter Reinisch, Klaus Gottlieb, Jean-Frederic Colombel, et al.
Clinical and Translational Gastroenterology|March 7, 2023
Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 StudyBoyd Steere, Jochen Schmitz, Nick Powell, et al.
Crohn'S & Colitis 360|April 24, 2026
Efficacy and safety of ABBV-154 in patients with moderately to severely active Crohn's disease: a phase 2b, randomized, double-blind, placebo-controlled trialWalter Reinisch, Laurent Peyrin-Biroulet, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|July 22, 2016
Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance StudiesOmoniyi J Adedokun, Zhenhua Xu, Colleen W Marano, et al.
Inflammatory Bowel Diseases|July 9, 2018
Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With GolimumabWalter Reinisch, Jean-Frederic Colombel, Peter R Gibson, et al.
Inflammatory Bowel Diseases|March 20, 2021
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical ProgramBruce E Sands, Millie D Long, Walter Reinisch, et al.
Tissue Barriers|June 28, 2022
Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn's disease and is responsive to filgotinibWalter Reinisch, Adrian Serone, Xavier Hébuterne, et al.
Inflammatory Bowel Diseases|May 20, 2015
Briakinumab for treatment of Crohn's disease: results of a randomized trialRemo Panaccione, William J Sandborn, Glenn L Gordon, et al.
Inflammatory Bowel Diseases|June 11, 2015
Ecobiotherapy Rich in Firmicutes Decreases Susceptibility to Colitis in a Humanized Gnotobiotic Mouse ModelJane M Natividad, Maria I Pinto-Sanchez, Heather J Galipeau, et al.
Journal of Crohn'S & Colitis|November 27, 2020
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical ProgrammeKevin L Winthrop, Edward V Loftus, Daniel C Baumgart, et al.
Pageof 36

Showing results (221-230 of 352) with videos related to

Sort By:
Pageof 36
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 30, 2019
Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug DevelopmentWalter Reinisch, Klaus Gottlieb, Jean-Frederic Colombel, et al.
Clinical and Translational Gastroenterology|March 7, 2023
Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 StudyBoyd Steere, Jochen Schmitz, Nick Powell, et al.
Crohn'S & Colitis 360|April 24, 2026
Efficacy and safety of ABBV-154 in patients with moderately to severely active Crohn's disease: a phase 2b, randomized, double-blind, placebo-controlled trialWalter Reinisch, Laurent Peyrin-Biroulet, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|July 22, 2016
Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance StudiesOmoniyi J Adedokun, Zhenhua Xu, Colleen W Marano, et al.
Inflammatory Bowel Diseases|July 9, 2018
Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With GolimumabWalter Reinisch, Jean-Frederic Colombel, Peter R Gibson, et al.
Inflammatory Bowel Diseases|March 20, 2021
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical ProgramBruce E Sands, Millie D Long, Walter Reinisch, et al.
Tissue Barriers|June 28, 2022
Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn's disease and is responsive to filgotinibWalter Reinisch, Adrian Serone, Xavier Hébuterne, et al.
Inflammatory Bowel Diseases|May 20, 2015
Briakinumab for treatment of Crohn's disease: results of a randomized trialRemo Panaccione, William J Sandborn, Glenn L Gordon, et al.
Inflammatory Bowel Diseases|June 11, 2015
Ecobiotherapy Rich in Firmicutes Decreases Susceptibility to Colitis in a Humanized Gnotobiotic Mouse ModelJane M Natividad, Maria I Pinto-Sanchez, Heather J Galipeau, et al.
Journal of Crohn'S & Colitis|November 27, 2020
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical ProgrammeKevin L Winthrop, Edward V Loftus, Daniel C Baumgart, et al.
Pageof 36